Avery Dennison Corporation (AVY)

CTI BioPharma Stock Forecast

Stock Price Forecast

The 10 analysts that cover CTI BioPharma stock have a consensus rating of "Buy" and an average price target of $197, which forecasts a 18.80% increase in the stock price over the next year. The lowest target is $175 and the highest is $210.

Price Target: $197.00 (+18.80%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$175	$197	$204	$210
Change	+5.54%	+18.80%	+23.02%	+26.64%

Analyst Ratings

The average analyst rating for CTI BioPharma stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Feb '25	Mar '25	Apr '25	May '25	Jun '25	Jul '25
Strong Buy	4	4	4	4	4	2
Buy	5	5	4	4	4	4
Hold	2	2	4	4	4	4
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	11	11	12	12	12	10

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
John McNulty BMO Capital	BMO Capital	Buy Reiterates $216 → $207	Buy	Reiterates	$216 → $207	+24.83%	Jul 23, 2025
Jeffrey Zekauskas JP Morgan	JP Morgan	Hold Maintains $172 → $182	Hold	Maintains	$172 → $182	+9.76%	Jul 23, 2025
Matt Roberts Raymond James	Raymond James	Buy Maintains $194 → $200	Buy	Maintains	$194 → $200	+20.61%	Jul 15, 2025
Anthony Pettinari Citigroup	Citigroup	Hold Maintains $177 → $185	Hold	Maintains	$177 → $185	+11.57%	Jul 11, 2025
George Staphos B of A Securities	B of A Securities	Strong Buy Maintains $195 → $208	Strong Buy	Maintains	$195 → $208	+25.44%	Jul 9, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

8.96B

Increased by 2.29%

from 8.76B

Revenue Next Year

9.30B

Increased by 3.85%

from 8.96B

EPS This Year

9.75

Increased by 11.65%

from 8.73

EPS Next Year

10.87

Increased by 11.47%

from 9.75

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Jan 2, 2021	Jan 1, 2022	Dec 31, 2022	Dec 30, 2023	Dec 28, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	6.97B	8.41B	9.04B	8.36B	8.76B	8.96B	9.30B	9.72B
Revenue Growth	-1.40%	20.61%	7.50%	-7.47%	4.68%	2.29%	3.85%	4.49%
EPS	6.61	8.83	9.21	6.20	8.73	9.75	10.87	12.09
EPS Growth	85.15%	33.59%	4.30%	-32.68%	40.81%	11.65%	11.47%	11.27%
Forward PE	-	-	-	-	-	17.01	15.26	13.72
No. Analysts	-	-	-	-	-	15	16	10

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027	2028	2029
High	9.5B	9.9B	10.4B
Avg	9.0B	9.3B	9.7B
Low	8.6B	8.8B	9.2B

Revenue Growth

Revenue Growth	2025	2026	2027	2028	2029
High	8.4%	10.7%	11.9%
Avg	2.3%	3.9%	4.5%
Low	-1.6%	-1.6%	-1.1%

EPS Forecast

EPS	2025	2026	2027	2028	2029
High	10.43	12.74	14.49
Avg	9.75	10.87	12.09
Low	9.26	10.14	11.07

EPS Growth

EPS Growth	2025	2026	2027	2028	2029
High	19.4%	30.7%	33.4%
Avg	11.7%	11.5%	11.3%
Low	6.1%	4.1%	1.9%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.